SynthesisClinical journal of the American Society of Nephrology : CJASN2017
Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis.
Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.Journal of diabetes · 2020Trial
- Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017Trial
- Bridging conventional clinical tests and advanced biomarkers for the early diagnosis of kidney disease progression.Pakistan journal of medical sciences · 2025Article
- Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.Frontiers in medicine · 2024Review
- Serum metabolomic signatures of plant-based diets and incident chronic kidney disease.The American journal of clinical nutrition · 2022Article
- β2-Microglobulin and β-Trace Protein in Patients Undergoing Bariatric Surgery: Non-GFR Determinants and Panel-estimated GFR Performance.Kidney medicine · 2022Article
- A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies.Toxicologic pathology · 2021Review
- The Role of Glomerular Epithelial Injury in Kidney Function Decline in Patients With Diabetic Kidney Disease in the TRIDENT Cohort.Kidney international reports · 2021Article
- Envelope method with ignorable missing data.Electronic journal of statistics · 2021Article
- New Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature.International journal of molecular sciences · 2020Review
- Serum kidney injury molecule 1 and βDiabetologia · 2019Article
- Prostaglandins in the pathogenesis of kidney diseases.Oncotarget · 2018Review
- Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.Advances in chronic kidney disease · 2018Review
- Novel Filtration Markers for GFR Estimation.EJIFCC · 2017Article
- Risk of ESRD and Mortality Associated With Change in Filtration Markers.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Observational
- Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.Frontiers in medicine · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 8 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesSerum β-trace protein (BTP) and β-2 microglobulin (B2M) are associated with risk of ESRD and death in the general population and in populations at high risk for these outcomes (GP/HR) and those with CKD, but results differ among studies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed an individual patient-level meta-analysis including three GP/HR studies (n=17,903 participants) and three CKD studies (n=5415). We compared associations, risk prediction, and improvement in reclassification of eGFR using BTP (eGFR
resultsMean (SD) follow up times for ESRD and mortality for GP/HR and CKD studies were 13 (4), 6.2 (3.2), 14 (5), and 7.5 (3.9) years, respectively. Compared with eGFR
conclusionsThese markers do not provide substantial additional prognostic information to eGFR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.